VPT:CC - Ventripoint Welcomes Evelina London Children's Hospital as Newest VMS+ User
(TheNewswire)
Toronto, Ontario – The Newswire –August 22, 2023 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce that Evelina LondonChildren’s Hospital (part of Guy's and StThomas' NHS Foundation Trust ) is the newest user to adopt the VMS+ 3.0 system upgrade.
Dr. Saleha Kabir, Lead Physiologist in Paediatrics andAdvanced Echocardiography stated: "Having had experience with theolder Ventripoint system, the new VMS + system with its increasedfunctionality is a great addition to our echo lab. The more compactconsole increases accessibility and mobility which allows us to use itin a variety of settings and the simplified workflow makes imageacquisition faster, which is fantastic for our small and easilydistracted paediatric patients!"
Evelina London Children’s Hospital is a specialistNHS hospital in London, England and is the second largest provider ofchildren’s services in London caring forchildren and young people from across south London and southeastEngland. Evalina London has a range ofchildren’s heart clinics including the fetal cardiology clinic andarrhythmia clinic. The children’s heart services (cardiology) caresfor around 6,000 patients each year with all kinds of children’sheart problems including:
-
those present from birth, known as congenital heartdisease.
-
those that develop after birth, known as acquiredheart disease.
-
rhythm disturbances.
The VMS+ 3.0 system will provide the paediatriccardiology team with a way to obtain accurate volumes of all fourchambers of the heart. The VMS+ uses standard 2D echo to obtain thenecessary metrics with the accuracy of a cardiac MRI. The VMS+ willsupport Evelina London’s patient load and have a positive impact inpatient care.
About Ventripoint DiagnosticsLtd.
Ventripoint has become an industry leader in theapplication of AI (Artificial Intelligence) to echocardiography.Ventripoint's VMS products are powered by its proprietary KBRtechnology, which is the result of a decade of development andprovides accurate volumetric cardiac measurements equivalent toMRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all of Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
For further information, pleasecontact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.